Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

NCT00695565 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.

Interventions

  • DRUG Placebo Gel
  • DRUG Clonidine Topical Gel (ARC-4558)

Study Locations (16)

California

  • Northern California Research — Sacramento
  • Neurological Research Institute — Santa Monica

Texas

  • The Nerve and Muscle Center of Texas — Houston
  • Diabetes and Glandular Disease Center — San Antonio

Alabama

  • University of Alabama at Birmingham, School of Medicine — Birmingham

Florida

  • Metabolic Research Institute — West Palm Beach

Kentucky

  • Pain Treatment Center of the Bluegrass — Lexington

Louisiana

  • Tulane University Health Sciences Center — New Orleans

Massachusetts

  • University of Massachuetts Medical School, Division of Diabetes- Clinical Research Office — Worcester

Nebraska

  • The Creighton Diabetes Center — Omaha

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2008-05
Est. Completion 2010-02
Phase Phase 2

Sponsor

Arcion Therapeutics

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00695565

The ClinicalTrials.gov registry entry for NCT00695565 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcion Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Painful Diabetic Neuropathy appearing as the primary indexed condition, and to 2 interventions — of which Placebo Gel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00695565 reports 16 study locations spanning 14 distinct geographic areas — top geographies include California, Texas, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00695565 about?

NCT00695565 is a clinical study titled "Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy". The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.

What is the current status of trial NCT00695565?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2008-05. Estimated completion is 2010-02.

What conditions does trial NCT00695565 study?

This clinical trial studies the following conditions: Painful Diabetic Neuropathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00695565?

The interventions under investigation include: Placebo Gel (DRUG), Clonidine Topical Gel (ARC-4558) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00695565?

This trial is sponsored by Arcion Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00695565 being conducted?

This trial has 16 study locations across Alabama, California, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial